Clinical Trial Readiness for Rare Diseases — R21 (Clinical Trials Not Allowed)
NIH/NCATS invites applications to fund studies that build clinical-trial readiness for rare diseases by developing or validating biomarkers, clinical outcome assessments (COAs), and natural history data needed to design rigorous future trials. Projects must not include interventional clinical trials, should focus on indications with candidate therapeutics and unmet needs, and are expected to l…
Attaining effective therapies for rare diseases is challenging due to their low prevalence resulting in fewer patients, clinicians, researchers, and resources compared to common diseases. This leads to gaps in our understanding of a rare disease's natural history, and a dearth of suitable biomar…
Funding Source
Awards & funding
Eligibility
Foreign/Non-domestic entities are NOT eligible: Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allow…
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers